Analytical Data
-
Gene name
MAGEB16
- Application
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9CWV4
-
Expression Region
Met1~Val363
-
Molecular Weight
65kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAGEB16, part of the MAGE (Melanoma Antigen Gene) family, is a gene primarily expressed in various cancer types, particularly melanoma. This gene encodes for a protein that is not typically present in normal adult tissues, making it a valuable target for cancer immunotherapy. The expression of MAGEB16 is closely associated with tumor progression, and its presence has been linked to poor prognosis in certain cancers. Research has focused on characterizing the structure and function of the MAGEB16 protein to understand its role in tumor biology and to explore its potential as a biomarker for cancer diagnosis and therapy. Furthermore, the immunogenic properties of MAGEB16 make it an attractive candidate for vaccine development, as it could elicit specific immune responses against tumor cells. Studies have also examined the regulatory mechanisms governing MAGEB16 expression, revealing insights into epigenetic factors that might contribute to its expression in malignancies. Overall, MAGEB16 represents a significant focal point in the search for targeted cancer therapies, due to its restricted expression profile and potential involvement in immune evasion by tumors. Researchers continue to investigate how MAGEB16 can be leveraged in combination with existing therapies to enhance treatment efficacy and improve outcomes for cancer patients.
